# US 2012/0252023 A1 · Materials and Methods Useful for Affecting Tumor Cell Growth, Migration and Invasion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252023 A1
- Document ID: US20120252023A1
- Status: Published application
- Kind: A1
- Application number: 13/511,474
- Filed: 2010-11-23
- Published: 2012-10-04
- Earliest claimed: 2009-11-23
- Assignees: The Ohio State University
- Inventors: Carlo M. Croce
- Web page: https://patentgrep.com/patent/US20120252023A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/11: Antisense
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein.

## Claims

### Claim 1

A method to alter the TRAIL Expression Pattern in a cell, comprising altering c-Jun, miR-221 and miR-222 and PTEN or TIMP3 in a cell capable of expressing c-Jun, miR-221 and miR-222, PTEN and TIMP3, and altering TRAIL Expression Pattern.

### Claim 2 (depends on 1)

A method of claim 1, comprising inhibiting or overexpressing c-Jun, miR-221 and miR-222, PTEN or TIMP3 in a cell capable of expressing c-Jun, miR-221 and miR-222, PTEN and TIMP3.

### Claim 3

A method to identify the TRAIL Expression Pattern in a cell sample, comprising identifying expression levels of at least two nucleic acids in a cell sample, wherein the at least two are selected from the group consisting of: miR-221 and miR-222 and c-Jun; miR-221 and miR-222 and PTEN; miR-221, miR-222 and TIMP3; miR-221 and miR-222, c-Jun and PTEN; miR-221 and miR-222, PTEN and TIMP3; and miR-221 and miR-222, c-Jun and TIMP3; and identifying TRAIL expression in the cell sample.

### Claim 4

A method to alter gene expression in a TRAIL-resistant cell, comprising altering miR-221 and miR-222 in a cell that also expresses at least one nucleic acid selected from the group consisting of: c-Jun; PTEN and TIMP3; and altering gene expression in the TRAIL-resistant cell.

### Claim 5 (depends on 4)

A method of claim 4, comprising inhibiting over-expressing miR-221 and miR-222 in a cell that also expresses at least one nucleic acid selected from the group consisting of: c-Jun; PTEN and TIMP3.

### Claim 6

A method to identify test cells having nucleic acid expression inhibition, comprising contacting at least one test cell with antisense miR-221 and miR-222; observing an increase in expression of a nucleic acid selected from the group consisting of: PTEN and TIMP3; and identifying the test cells having nucleic acid expression inhibition.

### Claim 7

A method of predicting clinical outcome of a patient diagnosed with cancer, comprising detecting the expression level of miR-221 and miR-222 and at least one nucleic expression level of a nucleic acid selected from the group consisting of: c-Jun; PTEN and TIMP3, in a cancer cell sample obtained from the patient; and predicting clinical outcome, wherein a 1.5-fold or greater increase in the level of miR-221 and miR-222 in combination with a 1.5-fold or greater decrease in the level of PTEN or TIMP3 expression in the tumor sample relative to a control predicts a decrease in survival, or wherein a 1.5-fold or greater increase in the level of miR-221 and miR-222 in combination with a 1.5-fold or greater increase in the level of c-Jun expression in the tumor sample relative to a control predicts a decrease in survival.

### Claim 8

A method to inhibit down-regulation of PTEN expression in a tumor cell that expresses miR-221 and miR-222 and PTEN, comprising inhibiting miR-221 and miR-222 activity in a tumor cell that expresses miR-221 and miR-222 and PTEN and inhibiting PTEN down-regulation in the tumor cell.

### Claim 9 (depends on 8)

A method of claim 8, wherein said miR-221 and miR-222 activity is inhibited via antisense miR-221 and miR-222.

### Claim 10 (depends on 8)

A method of claim 8, wherein PTEN expression down-regulation inhibition is observed via TRAIL, sensitivity.

### Claim 11 (depends on 8)

A method of claim 8, wherein PTEN expression down-regulation inhibition is observed via PTEN transcription analysis.

### Claim 12

A method to identify a therapeutic agent for the treatment of TRAIL-resistant cancer, comprising screening candidate agents in vitro to select an agent that decreases expression of miR-221 and miR-222 and increases expression of PTEN in a TRAIL-resistant cancer cell; and identifying a therapeutic agent for the treatment of TRAIL-resistance cancer.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method of claim 1, wherein said cell is selected from the group consisting of: cancer cell; TRAIL-resistant cancer cell; non-small cell lung carcinoma; and hepatocellular carcinoma.

### Claim 16

A method to alter regulation of TIMP3 expression in a cell capable of expressing TIMP3 and miR-221 and miR-222, comprising altering miR-221 and miR-222 activity in a TIMP3-expressing and miR-221 and miR-222-expressing cell and altering regulation of TIMP3 expression.

### Claim 17 (depends on 16)

A method of claim 16, comprising over-expressing miR-221 and miR-222 in a cell that also expresses TIMP3 and inhibiting TIMP3 expression.

### Claim 18 (depends on 16)

A method of claim 16, comprising contacting a test cell with antisense miR-221 and miR-222 and increasing TIMP3 expression.

### Claim 19

A method to identify TRAIL-resistant cells, comprising identifying whether a test cell sample comprises miR-221 and miR-222 nucleic acid and TIMP3 nucleic acid; and identifying TRAIL-resistant cells.

### Claim 20

A method to identify a therapeutic agent for the treatment of TRAIL-resistant cancer, comprising screening candidate agents in vitro to select an agent that decreases expression of miR-221 and miR-222 and increases expression of TIMP3 in a TRAIL-resistant cancer cell; and identifying an agent for the treatment of TRAIL-resistance cancer.

### Claim 21

A method of predicting clinical outcome of a patient diagnosed with cancer, comprising:
a) detecting the level of miR-221, miR-222 and TIMP3 expression in a cancer cell sample obtained from the patient,
b) predicting clinical outcome,
wherein a 1.5-fold or greater increase in the level of miR-221 and miR-222 in combination with a 1.5-fold or greater decrease in the level of TIMP3 expression in the tumor sample relative to a control predicts a decrease in survival.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 16)

A method of claim 16, wherein said cell is selected from the group consisting of: cancer cell; TRAIL-resistant cancer cell; non-small cell lung carcinoma; and hepatocarcinoma.

### Claim 25

A method to inhibit down-regulation of TIMP3 expression in a tumor cell that expresses miR-221, miR-222 and TIMP3, comprising inhibiting miR-221 and miR-222 activity in a tumor cell that expresses miR-221, miR-222 and TIMP3 and inhibiting down-regulation of TIMP3 expression.

### Claim 26 (depends on 25)

A method of claim 25, wherein said miR-221 and miR-222 activity is inhibited via antisense miR-221 and miR-222.

### Claim 27 (depends on 25)

A method of claim 25, wherein TIMP3 expression down-regulation inhibition is observed via TRAIL sensitivity.

### Claim 28 (depends on 25)

A method of claim 25, wherein TIMP3 expression down-regulation inhibition is observed via TIMP3 translation analysis.
